Research programme: histone deacetylase inhibitors - EntreMedAlternative Names: MKC-1313
Latest Information Update: 19 Dec 2008
At a glance
- Originator Miikana Therapeutics
- Developer EntreMed
- Mechanism of Action Apoptosis stimulants; Histone deacetylase inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 19 Dec 2008 Discontinued - Preclinical for Cancer in USA (unspecified route)
- 13 Jul 2007 Preclinical trials in Cancer in USA (unspecified route)